BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21092533)

  • 1. [Clinical characteristics of 34 children with Hodgkin lymphoma and efficacy of treatment with chemotherapy plus low dose radiotherapy on involved sites].
    Duan YL; Zhang YH; Jin L; Yang J; Zhang R; Zhou CJ
    Zhonghua Er Ke Za Zhi; 2010 Sep; 48(9):698-702. PubMed ID: 21092533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?
    Kahn S; Flowers C; Xu Z; Esiashvili N
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):175-80. PubMed ID: 20732769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
    Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.
    Campbell BA; Voss N; Pickles T; Morris J; Gascoyne RD; Savage KJ; Connors JM
    J Clin Oncol; 2008 Nov; 26(32):5170-4. PubMed ID: 18838714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy followed by low dose radiotherapy in childhood Hodgkin's disease: retrospective analysis of results and prognostic factors.
    Viani GA; Castilho MS; Novaes PE; Antonelli CG; Ferrigno R; Pellizzon CA; Fogaroli RC; Conte MA; Salvajoli JV
    Radiat Oncol; 2006 Oct; 1():38. PubMed ID: 17014708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and treatment outcome in childhood Hodgkin disease.
    Oguz A; Karadeniz C; Okur FV; Citak EC; Pinarli FG; Bora H; Akyurek N
    Pediatr Blood Cancer; 2005 Oct; 45(5):670-5. PubMed ID: 16007600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience.
    Gocheva L; Koleva I
    Klin Onkol; 2010; 23(1):34-42. PubMed ID: 20192072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
    Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
    J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-based combined-modality therapy of pediatric Hodgkin's lymphoma: a retrospective study.
    Ali A; Sayed H; Farrag A; El-Sayed M
    Leuk Res; 2010 Nov; 34(11):1447-52. PubMed ID: 20599270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease.
    Donaldson SS; Link MP; Weinstein HJ; Rai SN; Brain S; Billett AL; Hurwitz CA; Krasin M; Kun LE; Marcus KC; Tarbell NJ; Young JA; Hudson MM
    J Clin Oncol; 2007 Jan; 25(3):332-7. PubMed ID: 17235049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?
    Hamed RH; Anter AH; Awad IA
    Hematol Oncol Stem Cell Ther; 2012; 5(1):36-41. PubMed ID: 22446609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The treatment of childhood Hodgkin lymphoma: improved survival in a developing country.
    Büyükpamukçu M; Varan A; Akyüz C; Atahan L; Ozyar E; Kale G; Köksal Y; Kutluk T
    Acta Oncol; 2009; 48(1):44-51. PubMed ID: 18777215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable early-stage Hodgkin lymphoma.
    Yahalom J
    J Natl Compr Canc Netw; 2006 Mar; 4(3):233-40. PubMed ID: 16507270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hodgkin lymphoma in Tyrol-a population-based study.
    Fong D; Steurer M; Greil R; Gunsilius E; Spizzo G; Gastl G; Tzankov A
    Ann Hematol; 2009 May; 88(5):449-56. PubMed ID: 18846373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
    Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical characteristics and therapy outcome in children with stage IV Hodgkin's lymphoma--the experience of two oncological centres].
    Bień E; Stachowicz-Stencel T; Zawitkowska-Klaczyńska J; Adamkiewicz-Drozyńska E; Odój T; Połczyńska K; Mitura-Lesiuk M; Stefanowicz J; Sierota D; Szołkiewicz A; Birkholz D; Hennig M; Kowalczyk JR; Balcerska A
    Med Wieku Rozwoj; 2006; 10(3 Pt 1):631-8. PubMed ID: 17317894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx].
    Yuan ZY; Li YX; Zhao LJ; Gao YH; Liu XF; Gu DZ; Qian TN; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):425-9. PubMed ID: 15355649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
    Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
    Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.